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Frailty has emerged as a powerful predictor of outcomes in patients with cirrho‐
sis and has inevitably made its way into decision making within liver transplanta‐
tion. In an effort to harmonize integration of the concept of frailty among transplant 
centers, the AST and ASTS supported the efforts of our working group to develop 
this statement from experts in the field. Frailty is a multidimensional construct that 
represents the end‐manifestation of derangements of multiple physiologic systems 
leading to decreased physiologic reserve and increased vulnerability to health stress‐
ors. In hepatology/liver transplantation, investigation of frailty has largely focused on 
physical frailty, which subsumes the concepts of functional performance, functional 
capacity, and disability. There was consensus that every liver transplant candidate 
should be assessed at baseline and longitudinally using a standardized frailty tool, 
which should guide the intensity and type of nutritional and physical therapy in indi‐
vidual liver transplant candidates. The working group agreed that frailty should not 
be used as the sole criterion for delisting a patient for liver transplantation, but rather 
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1  | INTRODUC TION
Frailty has emerged as a fundamental force shaping the field of liver 
transplantation. Liver disease severity at transplantation is worsen‐
ing, the proportion of older adults (≥65 years) awaiting transplanta‐
tion is rising, and the prevalence of obesity‐related liver disease is 
rapidly escalating—all of which are contributing to a cohort of liver 
transplant patients who are sicker, more medically complex, and 
increasingly being described as “frail.” Clinicians caring for these 
patients have long intuited the importance of frailty on health out‐
comes before and after liver transplantation, even removing patients 
from the waitlist for being “too frail for transplant.” Yet despite the 
fact that the concept of frailty has inevitably made its way into trans‐
plant decision‐making, its integration into clinical transplant practice 
thus far has been haphazard, hindered by a lack of consensus on 
its definition, tools for assessment, and implications for transplant 
decision‐making.1
To overcome these barriers, the American Society of 
Transplantation supported the efforts of our working group of ex‐
perts in the field to develop this statement on frailty in liver trans‐
plantation. Our specific goals were to: (a) define frailty, (b) appraise 
tools for frailty measurement, and (c) develop an algorithm for prac‐
tical incorporation of frailty into clinical practice. While much of 
this document applies to patients with cirrhosis, regardless of their 
transplant eligibility, this statement was primarily intended for the 
transplant setting; we have highlighted specific areas in which our 
recommendations may differ whether or not the patient is listed for 
liver transplantation.
One word of caution when implementing our recommendations: 
we do not support the use of a one‐time assessment of frailty as the 
sole criterion for declining a patient for liver transplantation. Our 
goal with this document is to facilitate the systematic incorporation 
of a standardized frailty assessment for every patient at evaluation 
and longitudinally while awaiting liver transplantation in order to ac‐
curately capture progression of frailty on the waitlist as well as serve 
as the foundation for frailty intervention.
1.1 | Defining “frailty” in the setting of liver 
transplantation
The concept of frailty is most commonly defined as a distinct bio‐
logic syndrome of decreased physiologic reserve and increased vul‐
nerability to health stressors that predisposes one to adverse health 
outcomes.2 Frailty is a multidimensional construct, and represents 
the end‐manifestation of derangements of multiple physiologic sys‐
tems including all individual solid organ systems (eg, the liver, kidney, 
heart), inflammatory, endocrine, cognitive, and musculoskeletal sys‐
tems, as well as psychosocial factors.
While frailty has generally been conceptualized in the geriatrics 
arena as distinct from functional status, in the fields of hepatology/liver 
transplantation, the term “frailty” has largely focused on physical frailty 
(the aspect of frailty related to functional impairment) due to consider‐
ations of measurement in the hepatology and transplant settings. To be 
clear, functional status refers to one's ability to perform daily activities, 
fulfill social roles, and maintain health/well‐being3and subsumes the 
concepts of functional performance, functional capacity, and disability. 
In the context of liver transplantation, the focus on the physical func‐
tional aspects of frailty has the advantage over a broader conceptual‐
ization of frailty (that includes cognitive, social, and emotional aspects) 
given the need for objectivity of measurement. Although cognitive 
frailty is predictive of outcome in cirrhosis,4,5 the lack of standardized 
tools for the assessment of cognitive dysfunction in cirrhosis and the 
overlap with hepatic encephalopathy makes it difficult to objectively 
evaluate this more encompassing definition of frailty at this time. 
Importantly, “physical frailty,” as investigated in patients with cirrhosis, 
is a critical determinant of adverse health outcomes in this population, 
including waitlist mortality,6‐11 mortality after hospitalization and after 
liver transplantation,12‐15 need for hospitalization, length of stay,14,16‐18 
and discharge location (ie, rehabilitation facility)13,14 (Table 1).
Major components of frailty in all patients include skeletal 
muscle mass depletion (sarcopenia), progressive immobility, de‐
creased energy expenditure, and malnutrition.2 In patients with 
cirrhosis, there are multiple liver‐specific factors that exacerbate 
and accelerate this cycle of frailty (Figure 1). Chronic inflammation 
from the underlying liver disease is often the initial insult. Hepatic 
synthetic dysfunction results in the impairment of muscle protein 
synthetic response that can rapidly lead to progressive muscle 
breakdown. Anorexia associated with malaise (from chronic in‐
flammation) and early satiety (from ascites) leads to malnutrition, 
further accelerating muscle wasting. Hepatic encephalopathy and 
cognitive decline magnify the expression of frailty through multi‐
ple pathways, including altered taste perception, fatigue, immo‐
bility, and decreased energy expenditure. The obligatory shift of 
ammonia from liver to muscle for export as glutamine—diverting 
glutamate needed for muscle protein synthesis—is also recognized 
to be a pivotal driver of muscle wasting. Ammonia itself promotes 
should be considered one of many criteria when evaluating transplant candidacy and 
suitability. A road map to advance frailty in the clinical and research settings of liver 
transplantation is presented here.
K E Y W O R D S
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muscle autophagy, directly impairs contractility, and triggers syn‐
thesis and release of myotoxins contributing to sarcopenia.19 In 
addition to these liver‐related factors, patients with cirrhosis also 
experience non–liver‐related factors including chronologic aging, 
non‐hepatic comorbidities (eg, coronary artery disease, diabetic 
peripheral neuropathy), and age‐related muscle wasting. The con‐
tributions of these non–liver‐related factors are particularly im‐
portant for transplant decision‐making, as they are not modifiable 
and will not improve after transplantation.20
While sarcopenia is a central and dominant component of frailty in 
patients with cirrhosis, the concept of frailty is more multifaceted than 
sarcopenia alone. The inclusion of functional measures (eg, chair stands, 
gait speed) in validated frailty metrics suggests that the influence of sar‐
copenia may be modified by factors related to muscle function rather 
than purely muscle mass. Furthermore, the influence of patient‐reported 
outcomes (eg, exhaustion, sedentary time) implies that an individual's 
experience of their frailty state may also influence health outcomes. This 
consensus statement only addresses sarcopenia as it relates to the over‐
all construct of frailty; a separate working group has been assembled to 
more specifically address sarcopenia as a single entity.
Key points
• Frailty is a multidimensional construct that represents the end‐
manifestation of derangements of multiple physiologic systems 
that leads to decreased physiologic reserve and increased vulner‐
ability to health stressors.
• In hepatology/liver transplantation, the investigation of frailty has 
largely focused on physical frailty which subsumes the concepts of 
functional performance, functional capacity, and disability.
• While sarcopenia is a primary driver of frailty in patients with cir‐
rhosis, frailty is more multifaceted than sarcopenia alone, offering 
a comprehensive assessment of muscle function and the individual 
patient's experience of their frailty state in addition to muscle mass.
1.2 | Measuring frailty in adult liver 
transplant patients
Table 2 lists the tools to capture the construct of frailty that have 
been studied in patients with cirrhosis, including those awaiting 
liver transplantation. We, again, emphasize that the studies in this 
patient population have largely focused on the physical contributors 
to frailty, including functional performance, functional capacity, and 
disability.
In the research arena, frailty indices that best capture the multi‐
dimensionality of frailty such as the Fried Frailty Phenotype2 or the 
Frailty Index (“deficit model”21) may be necessary to demonstrate 
construct validity of new tools in patients with cirrhosis. However, 
these “traditional” models of frailty have limited applicability to the 
clinical practice of liver transplantation in that they are not contin‐
uously scored, display strong ceiling and/or floor effects, or are too 
complex to use in a busy clinical practice.1
With respect to the application of frailty tools in the clinical 
arena, we recommend that every transplant center should incorpo‐
rate a standardized tool to measure frailty in their liver transplant 
patients both at initial evaluation and longitudinally on the waitlist. 
This recommendation was based on evidence that standardized 
frailty metrics can improve the accuracy of the “eyeball test” and 
traditional liver disease metrics to predict mortality in patients with 
cirrhosis.5,7‐14,21
Given that there is no single frailty tool that has emerged in the 
literature as suitable for evaluation of patients with cirrhosis in all 
clinical scenarios (outpatient vs. inpatient; transplant vs. nontrans‐
plant), we recommend a frailty tool kit to provide a range of tools that 
can be used depending upon the clinical setting, available resources, 
and intended clinical decisions that will be made based on the test 
result. Here, we offer several points for each center to consider 
when deciding on which standardized frailty tool(s) to incorporate 
into clinical practice:
1. Frailty tools have been best studied in the outpatient setting. Measures 
such as the Fried Frailty Phenotype2 or Liver Frailty Index7 
have, to date, only been studied in the outpatient hepatology/
liver transplant settings where patients are in their “steady 
state.” Hospitalized patients often have transient perturbations 
in physical and cognitive function, which limit the ability of 
these performance‐based frailty assessments to represent true 
underlying physiologic reserve. However, while performance‐based 
tests may have limited use in the inpatient setting, provider‐ 
and patient‐assessed tools such as the Karnofsky Performance 
Status (KPS) and Activities of Daily Living (ADL) scale have been 
evaluated in the inpatient settings and demonstrated to predict 
F I G U R E  1   Liver‐related and non–
liver‐related factors that contribute to the 
development of physical frailty in patients 
with cirrhosis [Color figure can be viewed 
at wileyonlinelibrary.com]
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nontransplant mortality,11,14,15 re‐admissions,14,16 and mortality 
after liver transplantation.11
2. Subjective tools for “screening” versus more objective frailty as‐
sessment. Because of the potential implications of frailty in the 
decision to proceed with transplant, there was a consensus 
that waitlisted patients require assessment with objective, per‐ 
for mance‐based frailty tools (eg, Liver Frailty Index, 6‐minute 
walk test). Provider‐ or patient‐assessed metrics of frailty (eg, KPS, 
ADLs, Clinical Frailty Scale), while simple and feasible to administer 
systematically in a busy clinical setting, may be insensitive to sub‐
tle, but prognostic, gradients of the frailty spectrum. That being 
said, in the larger population of patients in the nontransplant set‐
ting, a stepwise approach where patients are screened with an 
“easy‐to‐perform” test, followed by a more comprehensive test 
to either confirm or definitively rule out frailty may be the most 
practical.
3. Measurement of longitudinal changes in frailty is clinically relevant 
in the transplant setting and requires frailty tools that are sensitive 
to change. Longitudinal changes in frailty are predictive of wait‐
list mortality above and beyond a single assessment alone.22 
Metrics such as the composite Liver Frailty Index, which is con‐
tinuous, lacks a floor/ceiling and has been shown to be reliable/
repro ducible,23 are particularly well‐suited for longitudinal meas‐
urement, although additional research is needed to validate 
the prognostic value of “Δfrailty” using the Liver Frailty Index. 
Identification of frailty tools that are sensitive to change is par‐
ticularly relevant as an endpoint for clinical trials aiming to slow 
the progression of—or even reverse—frailty.
Based on these three criteria, we offer a parsimonious tool kit con‐
sisting of the KPS scale, ADL/IADLs, Liver Frailty Index, and the 6‐min‐
ute walk test for transplant clinicians (Table 3). While no single tool is 
perfect for every clinical scenario, we selected these four tools specifi‐
cally to balance the needs for speed, low‐cost, patient‐centeredness, and 
objectivity.
1.3 | Measuring frailty in pediatric liver 
transplantation
A recent 17‐center study demonstrated that frailty assessment with 
the Fried Frailty Phenotype is feasible in school‐aged children with 
chronic liver disease; nearly half of children with end‐stage liver dis‐
ease met criteria for being frail.24 It is not yet known the extent to 
which frailty measures impact mortality. Metrics that incorporate 
performance‐based tests have limited application in infants and tod‐
dlers who may not be able to fully cooperate with testing instructions 
(eg, grip strength, chair stands). Frailty assessment in pediatric liver 
transplant patients < 5 years of age will likely require a combination of 
quantitative muscle mass measurement, laboratory and/or anthropo‐
metric nutritional biomarkers, and observed assessments of activity.
Key points
• Every patient with cirrhosis awaiting liver transplantation should be 
assessed at baseline and longitudinally using a standardized frailty tool.
• Frailty measurement with objective performance‐based measures 
(eg, Liver Frailty Index) is best studied in the outpatient setting 
when patients are in their “steady state.” However, provider‐ and 
patient‐assessed instruments (eg, KPS, ADLs) have prognostic 
value among hospitalized patients.
• To date, the Liver Frailty Index has the broadest applicability among 
all the frailty instruments for practical frailty assessment in the liver 
transplant setting and has the advantages of being objective, per‐
formance‐based, and suitable for longitudinal measurement.
1.4 | Incorporating frailty into clinical decision‐
making
We believe that a single assessment of frailty should not be used 
as the sole criterion for removing a patient from the liver transplant 
F I G U R E  2   A conceptual model of 
some of the patient components that 
clinicians incorporate into their global 
assessment of a patient's transplant 
candidacy and the tools that they use 
to inform this holistic assessment. An 
objective frailty tool kit should be used to 
inform clinicians’ assessments of muscle 
wasting, under‐nutrition, and physical 
inactivity—which, together, form the 
major components of physical frailty—to 
improve objectivity and accuracy of the 
clinician's global assessment of transplant 
candidacy for the purposes of transplant 
decision‐making (adapted from Lai JC, 
AJG 2017)8 [Color figure can be viewed at 
wileyonlinelibrary.com]
Global
Assessment of
Transplant
Candidacy
Patient Components
MELDNa
Child Pugh Score
Vital signs
Echocardiogram
Creatinine
Urinalysis
Spirometry,
Hemoglobin A1c,
Colonoscopy
Synthetic dysfunction
Portal hypertension
Measurement Tools
Cardiac function
Renal function
Other co-morbidities
Muscle wasting
Under-nutrition
Physical inactivity Objective Frailty Tool Kit
Eyeball test
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waitlist, as there are no data to support a single frailty cutoff at 
which a patient should not undergo liver transplantation. Instead, 
we advocate that a standardized tool for frailty be considered as one 
of many objective components that are routinely incorporated into 
a clinician's assessment of a patient's global health status that ulti‐
mately determines his or her transplant candidacy (Figure 2).8
Incorporating frailty into transplant decision‐making can offer 
the liver transplant community more than simply prognostication. 
What makes frailty such a unique risk factor for patients with cir‐
rhosis is that, unlike more “traditional” transplant risk factors such 
as age, sex, or Model for End‐Stage Liver Disease score, individual 
components of frailty (eg, physical function, sarcopenia, and mal‐
nutrition) are potentially modifiable with exercise and nutritional 
interventions.25,26
Recently, the concept of “prehabilitation” has gained signifi‐
cant momentum in transplant and nontransplant surgical fields.27 
Prehabilitation refers to multidisciplinary “training” to enhance 
physical strength and nutritional status—with the theoretical benefit 
of improving physiologic reserve prior to surgery. Although data on 
the impact of prehabilitation in liver transplantation are limited to a 
small cohort at a single center,27 there is emerging evidence in stud‐
ies of patients undergoing major abdominal surgeries that prehabil‐
itation programs improve outcomes and reduce costs. Examples of 
specific interventions have included comprehensive physical activ‐
ity programs, supervised and home‐based exercises, educational/
behavioral modification, and/or nutrition counseling.
Based on these data, we have developed a simple algorithm that 
leverages the potential “modifiability” of frailty through prehabilita‐
tion (Figure 3). Specifically, this algorithm uses a standardized frailty 
metric to guide recommendations regarding the intensity of preha‐
bilitation for liver transplant candidates. While our working group 
agreed that all liver transplant candidates should be provided exer‐
cise and nutritional recommendations, in light of limited availability 
of outpatient physical therapy and dietician resources—not to men‐
tion limited reimbursement—our algorithm allows for intensification 
of resources in those patients who are most vulnerable (ie, frail). 
The specific goals of this algorithm were to: (a) increase physiologic 
reserve pretransplant so that patients may better withstand acute 
decompensating events, (b) improve clinical outcomes after liver 
transplantation, and (c) more efficiently and effectively allocate 
healthcare resources in liver transplantation.
Our algorithm involves the following steps:
• Step 1: Stratify risk by frailty status. All liver transplant candidates 
should undergo risk stratification using a standardized frailty as‐
sessment tool. Our proposed frailty stratification system, based on 
expert opinion, for a select number of tools, is presented in Table 4.
• Step 2: Recommend a prehabilitation program based on risk stra‐
tum. The intensity of frailty intervention should be tailored to the 
degree of frailty. Patients with severe frailty may benefit from 
intensive prehabilitation, with consideration of referral to an in‐
patient rehabilitation center. We recommend that patients with 
a moderate degree of frailty engage in a home‐based exercise 
program developed by a certified exercise professional that tar‐
gets the patient's greatest functional impairment(s) (eg, balance, 
chair stands) but also incorporates aerobic training and simulates 
ADLs (to improve quality of life). Patients with mild or no frailty 
should follow recommendations developed for the general pop‐
ulation (ie moderate‐intensity exercise ≥ 150 minutes per week), 
with gradual build up physical endurance and strength. Physical 
activity trackers (eg, accelerometers) may be considered to assess 
adherence.
• Step 3: Reassess and re‐stratify. Reversal of frailty among liver 
transplant candidates is feasible but has not been systemat‐
ically studied. Lack of progression, however, is a clinically rele‐
vant achievement that should incentivize liver transplantation, 
F I G U R E  3   Algorithm to tailor 
prehabilitation recommendations based 
on frailty assessment [Color figure can be 
viewed at wileyonlinelibrary.com]
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particularly if early posttransplant rehabilitation will be provided. 
We recommend close monitoring of patients on the waitlist, with 
reassessment intervals based on the patient's severity of frailty at 
the last available examination (Figure 3).
Key points
• Standardized assessments of frailty may be used to tailor the in‐
tensity and type of nutritional and physical therapy in patients 
awaiting and undergoing liver transplantation.
• Frailty should not be used as the sole criterion for delisting a pa‐
tient for liver transplantation, but rather should be considered 
one of many criteria when evaluating transplant candidacy and 
suitability (Figure 2).
2  | A ROADMAP TO ADVANCE FR AILT Y IN 
THE CLINIC AL AND RESE ARCH SET TINGS 
OF LIVER TR ANSPL ANTATION
Frailty is now well‐recognized in the scientific literature as a strong 
predictor of outcomes in patients with cirrhosis, including in the 
liver transplant setting. While the frailty literature in hepatology/
liver transplantation is currently rich with high quality studies, many 
questions remain: (a) the impact of frailty on mortality after liver 
transplantation, (b) the impact of longitudinal changes in frailty on 
outcomes, and (c) the relationship between liver disease progression 
and frailty. Perhaps, the most exciting target for future investigation 
is the notion that frailty is actionable, and that its components can 
be arrested or even reversed. Here we propose a path forward to 
advance our understanding of frailty and improve the care of our 
patients:
Tool
Rationale for inclusion in the frailty 
tool kit
Estimated time 
to assess
Populations 
studied
Karnofsky perfor‐
mance status
Intuitive and instant <10 s Inpatient and 
outpatientNo cost
Low floor effects
Can be assessed by the patient or 
the provider
Activities of daily 
living/instrumental 
activities of daily 
living
No cost 2‐4 min Inpatient and 
outpatientPatient reported
Well‐accepted patient‐oriented 
outcome
Liver frailty index Objective, performance‐based 1‐3 min Outpatient
Continuous scale without ceiling or 
floor effects
Quickly administered
Can be repeatedly performed in 
the outpatient setting
6‐minute walk test Objective, performance‐based 6 min Outpatient
Continuous scale without ceiling or 
floor effects
No need for specialized equipment
TA B L E  3   Suggested frailty tool kit
Stages of frailty
Severe Moderate Mild/Absent
ADL14,31 Difficulty with ≥2 ADLs Difficulty with 1 
ADL
No difficulty 
with ADLs
Clinical Frailty Scale16 ≥7 6 1‐5
Fried Frailty Phenotype6 ≥3 1‐2 0
Karnofsky Performance 
Status Scale11,15
0‐40 50‐70 ≥80
Liver Frailty Index7 ≥4.5 3.2‐4.4 <3.2
6‐minute walk test9 <250 m <350‐250 m >350 m
Abbreviation: ADL, activities of daily living.
TA B L E  4   Recommended criteria to 
stage frailty in liver transplant candidates
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1. Obtain funding for multicenter consortia for prospective studies 
on frailty in liver transplantation. Now is an opportune time 
for formal financial sponsorship of multicenter consortia to 
accelerate progress. Engagement with other teams studying 
frailty in other chronic diseases, geriatrics/gerontology, and 
other solid organ transplant disciplines may have a high 
value.
2. Implement evidence‐based, objective frailty measurement as part of 
standard‐of‐care. Given its strong associations with health‐related 
outcomes, frailty should be considered a vital sign and measured 
systematically and routinely during clinic visits.
3. Develop interventions targeting modifiable aspects of physical frailty 
through rigorous multicenter randomized clinical trials. Specific modi‐
fiable targets include muscle mass, muscle function, activity level, 
and nutrition. Interventions can focus on a single aspect or offer 
a more comprehensive approach (eg, prehabilitation program). 
Randomization should offer clinical equipoise: because we believe 
that all patients with cirrhosis would benefit from some form of 
activity and nutritional counseling, trials should explore varying 
intensities (eg, two times per week vs. daily) or types of interven‐
tion (eg, home‐ vs. center‐based; telephone calls vs. text mes‐
sages) rather than randomizing patients to a “no intervention” arm.
4. Investigate nonphysical aspects of frailty. These include cognitive, 
emotional, social, and environmental aspects that expand the 
concept of frailty beyond physical frailty alone.
5. Integrate the concept of frailty into training curricula for hepa‐
tology/surgery trainees and into national society guidelines for 
management of patients with cirrhosis. Educational modules 
should be developed to assess transplant trainees’ ability to 
objectively assess, document, and incorporate frailty into clini‐
cal decision‐making. Assessment of frailty should be formally 
incorporated into national guidelines for evaluation of liver 
transplant candidates.
6. Include objective measurement of frailty into research studies and 
national registries. Frailty can be treated as a predictor, a con‐
founder, or even an outcome in research studies. Inclusion of ob‐
jective measurement of frailty into national registry data would 
accelerate research in this field and enable adjustment for frailty 
in any study evaluating pre‐ and posttransplant mortality. Based 
on the evidence to date and the need for uniformity of objective 
frailty measurement in this setting, we recommend use of the 
Liver Frailty Index for this purpose.
ACKNOWLEDG MENTS
This manuscript is a work product of the American Society of 
Transplantation's Liver and Intestine Community of Practice and 
has been endorsed by the American Society of Transplantation 
and the American Society of Transplant Surgeons. This study was 
funded by NIH K23AG048337 (Lai), NIH R01AG059183 (Lai), NIH 
RO1GM119174 (Dasarathy); P50 AA024333 (Dasarathy); R21AR 
71046 (Dasarathy); UO1 AA0026976 (Dasarathy); UO1DK061732 
(Dasarathy); RO1DK113196 (Dasarathy); Mikati Foundation Grant 
(Dasarathy). These funding agencies played no role in the analysis of 
the data or the preparation of this manuscript.
DISCLOSURE
The authors of this manuscript have no conflict of interest to dis‐
close as described by the American Journal of Transplantation.
DATA AVAIL ABILIT Y S TATEMENT
Data sharing not applicable to this article as no datasets were gener‐
ated or analyzed during the current study.
ORCID
Shunji Nagai  https://orcid.org/0000‐0003‐2612‐8427 
R E FE R E N C E S
 1. Lai JC. Advancing adoption of frailty to improve the care of pa‐
tients with cirrhosis: time for a consensus on a frailty index. Am J 
Gastroenterol. 2016;111(12):1776‐1777.
 2. Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: evidence 
for a phenotype. J Gerontol A Biol Sci Med Sci. 2001;56(3):146‐156.
 3. American Thoracic Society: Quality Life Resource. Functional 
Status. Available at: http://qol.thora cic.org/secti ons/key‐conce 
pts/funct ional‐status.html. Accessed February 23, 2018.
 4. Ney M, Tangri N, Dobbs B, et al. Predicting hepatic encephalopa‐
thy‐related hospitalizations using a composite assessment of cog‐
nitive impairment and frailty in 355 patients with cirrhosis. Am J 
Gastroenterol. 2018;113(10):1‐10.
 5. Tapper EB, Konerman M, Murphy S, Sonnenday CJ. Hepatic en‐
cephalopathy impacts the predictive value of the Fried Frailty 
Index. Am J Transplant. 2018;18(10):2566‐2570.
 6. Lai JC, Feng S, Terrault NA, Lizaola B, Hayssen H, Covinsky K. 
Frailty predicts waitlist mortality in liver transplant candidates. Am 
J Transplant. 2014;14(8):1870‐1879.
 7. Lai JC, Covinsky KE, Dodge JL, et al. Development of a novel frailty 
index to predict mortality in patients with end‐stage liver disease. 
Hepatology. 2017;66(2):564‐574.
 8. Lai JC, Covinsky KE, McCulloch CE, Feng S. The liver frailty index 
improves mortality prediction of the subjective clinician assess‐
ment in patients with cirrhosis. Am J Gastroenterol. 2017;10:1‐8.
 9. Carey EJ, Steidley DE, Aqel BA, et al. Six‐minute walk distance 
predicts mortality in liver transplant candidates. Liver Transpl. 
2010;16(12):1373‐1378.
 10. Ney M, Haykowsky MJ, Vandermeer B, Shah A, Ow M, Tandon P. 
Systematic review: pre‐ and post‐operative prognostic value of 
cardiopulmonary exercise testing in liver transplant candidates. 
Aliment Pharmacol Ther. 2016;44(8):796‐806.
 11. Orman ES, Ghabril M, Chalasani N. Poor performance status is 
associated with increased mortality in patients with cirrhosis. Clin 
Gastroenterol Hepatol. 2016;14(8):1189‐1195.e1.
 12. Faustini Pereira JXL, Galant LH, Rossi D, et al. Functional capac‐
ity, respiratory muscle strength, and oxygen consumption predict 
mortality in patients with cirrhosis. Can J Gastroenterol Hepatol. 
2016;2016(1):1‐6.
 13. Sundaram V, Lim J, Tholey DM, et al. The Braden Scale, a standard 
tool for assessing pressure ulcer risk, predicts early outcomes after 
liver transplantation. Liver Transpl. 2017;23(9):1153‐1160.
1906  |     LAI et AL.
 14. Tapper EB, Finkelstein D, Mittleman MA, Piatkowski G, Lai 
M. Standard assessments of frailty are validated predictors of 
mortality in hospitalized patients with cirrhosis. Hepatology. 
2015;62(2):584‐590.
 15. Tandon P, Reddy KR, O'Leary JG, et al. A Karnofsky performance 
status‐based score predicts death after hospital discharge in pa‐
tients with cirrhosis. Hepatology. 2017;65(1):217‐224.
 16. Tandon P, Tangri N, Thomas L, et al. A rapid bedside screen to pre‐
dict unplanned hospitalization and death in outpatients with cir‐
rhosis: a prospective evaluation of the clinical frailty scale. Am J 
Gastroenterol. 2016;111(12):1759‐1767.
 17. Dunn MA, Josbeno DA, Tevar AD, et al. Frailty as tested by gait speed 
is an independent risk factor for cirrhosis complications that require 
hospitalization. Am J Gastroenterol. 2016;111(12):1768‐1775.
 18. Sinclair M, Poltavskiy E, Dodge JL, Lai JC. Frailty is independently 
associated with increased hospitalisation days in patients on the 
liver transplant waitlist. World J Gastroenterol. 2017;23(5):899.
 19. Dasarathy S, Merli M. Sarcopenia from mechanism to diagnosis and 
treatment in liver disease. J Hepatol. 2016;65(6):1232‐1244.
 20. Lai JC. A framework to determine when liver transplantation is fu‐
tile. Clin Liver Dis. 2016;8(6):137‐139.
 21. Rockwood K, Mitnitski A. Frailty in relation to the accumulation of 
deficits. J Gerontol A Biol Sci Med Sci. 2007;62(7):722‐727.
 22. Lai JC, Dodge JL, Sen S, Covinsky K, Feng S. Functional decline in 
patients with cirrhosis awaiting liver transplantation: results from 
the Functional Assessment in Liver Transplantation (FrAILT) study. 
Hepatology. 2016;63:574‐580.
 23. Wang CW, Lebsack A, Chau S, Lai JC. The range and reproducibility 
of the Liver Frailty Index (published online ahead of print March 
2019). Liver Transpl. https ://doi.org/10.1002/lt.25449 ..
 24. Lurz E, Quammie C, Englesbe M, et al. Frailty in children with liver dis‐
ease: a prospective multicenter study. J Pediatr. 2018;194:109‐115.
 25. Duarte‐Rojo A, Ruiz‐Margáin A, Montano‐Loza AJ, Macías‐
Rodríguez RU, Ferrando A, Kim WR. Exercise and physical activity 
for patients with end‐stage liver disease: improving functional sta‐
tus and sarcopenia while on the transplant waiting list. Liver Transpl. 
2017;24(1):122‐139.
 26. Tandon P, Ismond KP, Riess K, et al. Exercise in cirrhosis: translating 
evidence and experience to practice. J Hepatol. 2018;69:1164‐1177.
 27. Volk ML, Sonnenday C. Patient‐centered liver transplantation. Clin 
Liver Dis. 2016;8(1):24‐27.
 28. Samoylova ML, Covinsky KE, Haftek M, Kuo S, Roberts JP, Lai JC. 
Disability in patients with end‐stage liver disease: results from the 
functional assessment in liver transplantation study. Liver Transpl. 
2017;23(3):292‐298.
 29. Malinis MF, Chen S, Allore HG, Quagliarello VJ. Outcomes among 
older adult liver transplantation recipients in the model of end stage 
liver disease (MELD) era. Ann Transplant. 2014;19:478‐487.
 30. Yadav A, Chang Y‐H, Carpenter S, et al. Relationship between sar‐
copenia, six‐minute walk distance and health‐related quality of life 
in liver transplant candidates. Clin Transpl. 2015;29(2):134‐141.
 31. Rakoski MO, McCammon RJ, Piette JD, et al. Burden of cirrhosis 
on older Americans and their families: analysis of the health and 
retirement study. Hepatology. 2012;55(1):184‐191.
How to cite this article: Lai JC, Sonnenday CJ, Tapper EB, 
et al. Frailty in liver transplantation: An expert opinion 
statement from the American Society of Transplantation 
Liver and Intestinal Community of Practice. Am J Transplant. 
2019;19:1896‐1906. https ://doi.org/10.1111/ajt.15392 
